In the Boardroom - Forest Laboratories, UK, Germany

Filter

1 to 25 of 305 results

Jacques Servier, founder and president of Lab Servier, dies aged 92

17-04-2014

French independent drugmaker Laboratories Servier announced that its founder and president, Jacques Servier,…

BoardroomManagementPharmaceuticalServier

Lost sales could reach $32 billion by 2022 as cancer drugs hit patent cliff

Lost sales could reach $32 billion by 2022 as cancer drugs hit patent cliff

17-04-2014

Over $17 billion of sales will be at risk in 2018/19 as many of the top performing oncology drugs lose…

AlimtaCancerChemistryEli LillyFinancialFranceGenericsGermanyHealth Medical PharmaHerceptinItalyJapanJohnson & JohnsonOncologyPatentsPharmaceuticalPharmaceutical sciencesPharmacologyRocheSpainUKUSAVelcade

Boehringer Ingelheim’s volasertib granted orphan drug designation for AML

Boehringer Ingelheim’s volasertib granted orphan drug designation for AML

17-04-2014

The US Food and Drug Administration and the European Commission have granted German family-owned drug…

Boehringer IngelheimEuropeGermanyHealth Medical PharmaMajorMedicineOncologyPharmaceuticalPharmacologyRegulationUS Food and Drug AdministrationUSAvolasertib

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

16-04-2014

The US subsidiary of Japanese drug major Astellas Pharma announced that Jeffrey Bloss has been promoted…

Astellas PharmaBoardroomManagementPharmaceuticalUSA

NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

15-04-2014

In final draft guidance published today, the UK’s National Institute for Health and Care Excellence…

AnatomyCare ExcellenceFerring PharmaceuticalsFirmagonHealth Medical PharmaMedicineOncologyPharmaceuticalRegulationUKUnited Kingdom

GSK faces bribery allegations in Poland

GSK faces bribery allegations in Poland

14-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribing doctors in Poland, according to the…

BBCGlaxoSmithKlineGSK regional managerLegalMajorMedicinePharmaceuticalPolandPulmonologyRespiratory and PulmonarySeretideUK

Bionovis and Merck KGaA sign agreement to produce eight biosimilars

Bionovis and Merck KGaA sign agreement to produce eight biosimilars

14-04-2014

Brazilian biotech company Bionovis and Germany’s Merck KGaA have signed an agreement for the development…

Anti-Arthritics/RheumaticsBionovisBiosimilar productsBiosimilarsBrazilBrazilian governmentGermanyHealth Medical PharmaHealth Medical PharmaMerck KGaAOncologyProductionTreatment of cancer

Herceptin patents ruled invalid by UK High Court leaving Hospira to launch generic

Herceptin patents ruled invalid by UK High Court leaving Hospira to launch generic

11-04-2014

The UK’s High Court has ruled that two patents on Swiss drug major Roche’s breast cancer drug Herceptin…

GenericsHealth Medical PharmaHealth Medical PharmaHerceptinHigh CourtHospiraLegalMylanOncologyPatents & Trade marksPharmaceuticalRocheTrastuzumabUK

New UK report finds divide between personalized medicines R&D and regulatory environment

New UK report finds divide between personalized medicines R&D and regulatory environment

11-04-2014

Over half of the active products in the global industry research pipeline are personalized medicines…

Chief executiveHealth Medical PharmaHealthcareImmunologicalsPharmaceuticalPharmaceutical sciencesPharmacologyResearchStephen WhiteheadUK

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Tamiflu use called into question by UK report

Tamiflu use called into question by UK report

10-04-2014

The UK government and health policy decision makers are being called upon to review the guidance on the…

Antibiotics and Infectious diseasesChemistryDavid ToveyGlaxoSmithKlineHealthcareMajorPharmaceuticalRelenzaResearchRocheTamifluThe British Medical JournalUKUK government

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

09-04-2014

US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

London Mayor Boris Johnson launches MedCity to boost UK life sciences research

London Mayor Boris Johnson launches MedCity to boost UK life sciences research

08-04-2014

The Mayor of London Boris Johnson today launched a major new initiative backed by some of the UK’s…

PharmaceuticalResearchUK

UK’s ValiRx forms joint venture to fast track lung cancer drug to Phase II

UK’s ValiRx forms joint venture to fast track lung cancer drug to Phase II

08-04-2014

UK biopharmaceutical company ValiRx has established ValiSeek, a joint venture company with Tangent Reprofiling.

Chief executiveLicensingLung cancerOncologyPharmaceuticalResearchScienceUKValiRxValiSeek

GSK faces fresh allegations of “inproper conduct” in Iraq

GSK faces fresh allegations of “inproper conduct” in Iraq

08-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribery in Iraq, less than a year after the…

ChinaGlaxoSmithKlineGSKIraqMajorPharmaceuticalRegulationUK

UK’s NICE says “yes” to Genzyme’s MS drug Lemtrada

04-04-2014

In final draft guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE)…

BiotechnologyGenzymeLemtradaNeurologicalNorthern EuropeRegulationSanofiUK

UK’s NICE reverses negative decision on Roche’s Tarceva for NSCLC

04-04-2014

Following a consultation period, the UK drug watchdog the National Institute for Health and Care Excellence…

Northern EuropeOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

UK Pharma moves on transparency of financial relationships with health professionals

03-04-2014

The UK’s pharmaceutical industry today announced another step towards greater transparency by revealing…

FinancialNorthern EuropePharmaceuticalResearchUK

New Haven Pharmaceuticals appoints Larry Dillaha as Executive Vice President Operations

New Haven Pharmaceuticals appoints Larry Dillaha as Executive Vice President Operations

02-04-2014

New Haven Pharmaceuticals, a privately held specialty pharmaceuticals company, today announced the appointment…

BoardroomNew Haven PharmaceuticalsPharmaceuticalUSA

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

02-04-2014

UK pharma major GlaxoSmithKline will stop its MAGRIT trial, a Phase III trial of its MAGE-A3 cancer immunotherapeuticin…

GlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearchUK

Paul Sekhri joins Sanofi as Senior Vice President

Paul Sekhri joins Sanofi as Senior Vice President

01-04-2014

Paul Sekhri has joined French drug major Sanofi as Senior Vice President, Integrated Care effective…

BiotechnologyBoardroomPharmaceuticalSanofiUSA

1 to 25 of 305 results

Company Spotlight

Fibrotech

Fibrotech

Back to top